HomeCompareSCLN vs NOBL

SCLN vs NOBL: Dividend Comparison 2026

SCLN yields 17.94% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCLN wins by $41.4K in total portfolio value
10 years
SCLN
SCLN
● Live price
17.94%
Share price
$11.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$5,372.32
Full SCLN calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SCLN vs NOBL

📍 SCLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCLNNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCLN + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCLN pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCLN
Annual income on $10K today (after 15% tax)
$1,524.66/yr
After 10yr DRIP, annual income (after tax)
$4,566.47/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SCLN beats the other by $4,354.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCLN + NOBL for your $10,000?

SCLN: 50%NOBL: 50%
100% NOBL50/50100% SCLN
Portfolio after 10yr
$43.6K
Annual income
$2,811.05/yr
Blended yield
6.45%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCLN buys
0
NOBL buys
0
No recent congressional trades found for SCLN or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCLNNOBL
Forward yield17.94%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$64.3K$22.9K
Annual income after 10y$5,372.32$249.78
Total dividends collected$34.5K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SCLN vs NOBL ($10,000, DRIP)

YearSCLN PortfolioSCLN Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$12,494$1,793.72$10,917$217.08+$1.6KSCLN
2$15,463$2,094.42$11,903$221.48+$3.6KSCLN
3$18,968$2,422.55$12,962$225.68+$6.0KSCLN
4$23,073$2,777.26$14,099$229.68+$9.0KSCLN
5$27,845$3,157.31$15,319$233.49+$12.5KSCLN
6$33,355$3,561.10$16,628$237.10+$16.7KSCLN
7$39,677$3,986.73$18,033$240.53+$21.6KSCLN
8$46,886$4,432.07$19,539$243.78+$27.3KSCLN
9$55,063$4,894.76$21,154$246.86+$33.9KSCLN
10$64,290$5,372.32$22,884$249.78+$41.4KSCLN

SCLN vs NOBL: Complete Analysis 2026

SCLNStock

SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company acquires, develops, and commercializes drugs for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.

Full SCLN Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SCLN vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCLN vs SCHDSCLN vs JEPISCLN vs OSCLN vs KOSCLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.